Texas Capital Bank Wealth Management Services Inc Has $14.54 Million Holdings in Eli Lilly and Company $LLY

Key Points

• Texas Capital Bank Wealth Management Services increased its Eli Lilly stake by 10.3% in the fourth quarter, ending with 13,533 shares worth about $14.54 million. The stock now represents roughly 0.8% of the firm’s portfolio.
• Institutional ownership remains high, with investors holding 82.53% of Eli Lilly’s shares. The article also notes several other funds made new purchases or boosted their positions.
• Analyst sentiment is still broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $1,227. Recent reports include multiple price-target increases, though one firm downgraded the stock to Hold.

Texas Capital Bank Wealth Management Services Inc lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,533 shares of the company's stock after purchasing an additional 1,264 shares during the quarter. Eli Lilly and Company makes up about 0.8% of Texas Capital Bank Wealth Management Services Inc's investment portfolio, making the stock its 22nd largest position. Texas Capital Bank Wealth Management Services Inc's holdings in Eli Lilly and Company were worth $14,544,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after acquiring an additional 16 shares during the last quarter. 10Elms LLP raised its position in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after acquiring an additional 10 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after acquiring an additional 24 shares during the last quarter. Finally, Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $33,000. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LLY. Bank of America boosted their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a "buy" rating in a research report on Tuesday. Zacks Research cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Friday, January 30th. Guggenheim reaffirmed a "buy" rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Daiwa Securities Group lifted their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $1,344.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus target price of $1,227.00.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company in a combined deal worth up to $3.83 billion, expanding its vaccine and infectious-disease pipeline. Lilly announces three acquisitions to build infectious disease portfolio
• Positive Sentiment: The acquisition spree is being viewed as a strategic move to diversify Lilly’s business and leverage the cash flow generated by its obesity franchise into adjacent high-value markets. Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
• Positive Sentiment: LLY has also been hitting record highs and became the first pharmaceutical company valued at $1 trillion, reinforcing the market’s confidence in its growth story. Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion
• Neutral Sentiment: Additional coverage highlighted continued investor attention around Lilly’s momentum, analyst optimism, and its participation in a Goldman Sachs healthcare conference, but these items are less likely to move the stock on their own. Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
• Neutral Sentiment: Articles comparing Lilly with Novo Nordisk and discussing Trump’s stock purchases do not appear to change the core investment thesis, with Lilly’s fundamentals still seen as the main driver. President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?
• Neutral Sentiment: Competition concerns around Novo Nordisk in the obesity-pill market were framed as manageable rather than a major threat. Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

Eli Lilly and Company Stock Up 1.9%

NYSE:LLY opened at $1,085.36 on Thursday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 38.56, a PEG ratio of 1.16 and a beta of 0.48. The stock has a 50-day moving average price of $948.23 and a two-hundred day moving average price of $1,007.67.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. During the same period in the previous year, the firm earned $3.34 earnings per share. The company's revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.